CC
TRIL

Commodore Capital’s Trillium Therapeutics Inc. TRIL Stock Holding History

Commodore Capital’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-795,868
Closed -$8.55M – 33
2021
Q1 		$8.55M Sell
795,868
-57,003
-7% -$705K 3.41% 12
2020
Q4 		$12.5M Buy
+852,871
New +$12.3M 6.82% 2

Other funds holding TRIL

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Commodore Capital's TRIL Position: Q2 2021 in Review

Commodore Capital sold out of Trillium Therapeutics Inc. (TRIL) in Q2 2021, closing a stake of 795,868 shares — an estimated $8.55M sold.

Commodore Capital first reported a position in TRIL in Q4 2020 and held it in 2 quarters. The position peaked at $12.5M in Q4 2020. 137 funds tracked by Wall St. Rank hold TRIL as of Q2 2021.

  • Commodore Capital reported no remaining Trillium Therapeutics Inc. position as of Q2 2021 after selling out during the quarter.
  • Commodore Capital sold 795,868 Trillium Therapeutics Inc. shares in Q2 2021, an estimated $8.55M.
  • Commodore Capital first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 2 quarters.
  • Commodore Capital's Trillium Therapeutics Inc. position peaked at $12.5M in Q4 2020.
  • 137 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q2 2021.

Based on Commodore Capital's 13F filing for Q2 2021, filed 16 Aug 2021.